REGENERON PHARMACEUTICALS, INC. (REGN) Operating Margin
- Operating margin · 12 months: Value 24.74%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 24.74% | Operating income / revenue. Period ending 2026-06-30. $3.84B ÷ $15.53B × 100 ≈ 24.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 3.84B USD | Operating Income (Loss) |
| Revenue | 15.53B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 6.28B USD | Research and Development Expense |
| Selling, general and administration | 2.74B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.84B | $15.53B | (m) | $6.28B | $2.74B | 24.74% |
| 2026-03-31 | $3.63B | $14.92B | (m) | $6.07B | $2.71B | 24.32% |
| 2025-12-31 | $3.58B | $14.34B | (m) | $5.85B | $2.70B | 24.95% |
| 2025-09-30 | $3.69B | $14.25B | (m) | $5.64B | $2.72B | 25.89% |
| 2025-06-30 | $3.84B | $14.21B | (m) | $5.43B | $2.77B | 27.02% |
| 2025-03-31 | $3.83B | $14.09B | (m) | $5.21B | $2.90B | 27.20% |
| 2024-12-31 | $3.99B | $14.20B | (m) | $5.13B | $2.95B | 28.10% |
| 2024-09-30 | $3.97B | $13.85B | (m) | $4.90B | $2.90B | 28.69% |
| 2024-06-30 | $3.90B | $13.49B | (m) | $4.70B | $2.83B | 28.95% |
| 2024-03-31 | $3.85B | $13.10B | (m) | $4.59B | $2.72B | 29.40% |
| 2023-12-31 | $4.05B | $13.12B | (m) | $4.44B | $2.63B | 30.85% |
| 2023-09-30 | $4.22B | $13.10B | (m) | $4.30B | $2.55B | 32.23% |
| 2023-06-30 | $4.33B | $12.67B | (m) | $4.14B | $2.44B | 34.20% |
| 2023-03-31 | $4.43B | $12.37B | (m) | $3.85B | $2.27B | 35.79% |
| 2022-12-31 | $4.74B | $12.17B | (m) | $3.59B | $2.12B | 38.93% |
| 2022-09-30 | $6.23B | $13.71B | (m) | $3.33B | $2.02B | 45.45% |
| 2022-06-30 | $6.86B | $14.23B | (m) | $3.09B | $1.93B | 48.19% |
| 2022-03-31 | $9.09B | $16.51B | (m) | $3.01B | $1.87B | 55.08% |
| 2021-12-31 | $8.95B | $16.07B | (m) | $2.91B | $1.82B | 55.67% |
| 2021-09-30 | $7.47B | $13.54B | (m) | $2.87B | $1.57B | 55.19% |
| 2021-06-30 | $6.68B | $12.38B | (m) | $2.89B | $1.45B | 53.94% |
| 2021-03-31 | $3.99B | $9.20B | (m) | $2.89B | $1.38B | 43.37% |
| 2020-12-31 | $3.58B | $8.50B | (m) | $2.73B | $1.35B | 42.09% |
| 2020-09-30 | $3.09B | $9.24B | (m) | $3.13B | $1.99B | 33.38% |
| 2020-06-30 | $2.77B | $8.69B | (m) | $2.97B | $1.96B | 31.87% |
| 2020-03-31 | $2.43B | $8.32B | (m) | $3.13B | $1.91B | 29.21% |
| 2019-12-31 | $2.21B | $7.86B | (m) | $3.04B | $1.83B | 28.10% |
| 2019-09-30 | $2.25B | $7.62B | (m) | $2.95B | $1.74B | 29.55% |
| 2019-06-30 | $2.14B | $7.24B | (m) | $2.85B | $1.69B | 29.58% |
| 2019-03-31 | $2.45B | $6.91B | (m) | $2.33B | $1.64B | 35.41% |
| 2018-12-31 | $2.53B | $6.71B | (m) | $2.19B | $1.56B | 37.77% |
| 2018-09-30 | $2.36B | $6.37B | (m) | $2.11B | $1.47B | 37.00% |
| 2018-06-30 | $2.29B | $6.20B | (m) | $2.09B | $1.41B | 36.89% |
| 2018-03-31 | $2.22B | $6.06B | (m) | $2.07B | $1.35B | 36.54% |
| 2017-12-31 | $2.08B | $5.87B | (m) | $2.08B | $1.32B | 35.41% |
| 2017-09-30 | $1.89B | $5.52B | (m) | $2.03B | $1.24B | 34.22% |
| 2017-06-30 | $1.69B | $5.24B | (m) | $2.04B | $1.20B | 32.29% |
| 2017-03-31 | $1.43B | $4.98B | (m) | $2.09B | $1.18B | 28.76% |
| 2016-12-31 | $1.33B | $4.86B | (m) | $2.05B | $1.18B | 27.38% |
| 2016-09-30 | $1.21B | $4.73B | (m) | $2.03B | $1.15B | 25.67% |
| 2016-06-30 | $1.24B | $4.65B | (m) | $1.92B | $1.09B | 26.77% |
| 2016-03-31 | $1.30B | $4.43B | (m) | $1.75B | $969.21M | 29.26% |
| 2015-12-31 | $1.25B | $4.10B | (m) | $1.62B | $838.53M | 30.51% |
| 2015-09-30 | $1.24B | $3.81B | (m) | $1.51B | $718.88M | 32.47% |
| 2015-06-30 | $1.03B | $3.40B | (m) | $1.42B | $652.89M | 30.41% |
| 2015-03-31 | $915.91M | $3.06B | (m) | $1.33B | $575.03M | 29.90% |
| 2014-12-31 | $838.43M | $2.82B | (m) | $1.27B | $504.75M | 29.74% |
| 2014-09-30 | $803.14M | $2.63B | (m) | $1.19B | $443.10M | 30.56% |
| 2014-06-30 | $857.22M | $2.50B | (m) | $1.07B | $390.96M | 34.30% |
| 2014-03-31 | $792.92M | $2.29B | (m) | $967.03M | $361.00M | 34.61% |
| 2013-12-31 | $760.03M | $2.10B | (m) | $859.95M | $329.42M | 36.11% |
| 2013-09-30 | $693.63M | $1.91B | (m) | $772.83M | $305.07M | 36.34% |
| 2013-06-30 | $659.19M | $1.74B | (m) | $707.08M | $254.34M | 37.89% |
| 2013-03-31 | $588.56M | $1.59B | (m) | $666.99M | $229.59M | 37.10% |
| 2012-12-31 | $457.71M | $1.38B | (m) | $625.55M | $210.75M | 33.20% |
| 2012-09-30 | $266.64M | $1.09B | (m) | $573.57M | $189.37M | 24.53% |
| 2012-06-30 | $5.82M | $762.00M | (m) | $543.20M | $175.40M | 0.76% |
| 2012-03-31 | $-141.98M | $565.41M | (m) | $538.98M | $152.28M | -25.11% |
| 2011-12-31 | $-205.16M | $445.82M | (m) | $529.51M | $117.26M | -46.02% |
| 2011-09-30 | $-172.53M | $456.52M | (m) | $525.68M | $101.55M | -37.79% |
| 2011-06-30 | $-146.17M | $459.67M | (m) | $519.80M | $84.30M | -31.80% |
| 2011-03-31 | $-109.58M | $467.74M | (m) | $501.17M | $74.39M | -23.43% |
| 2010-12-31 | $-97.47M | $459.07M | (m) | $489.25M | $65.20M | -21.23% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-74.10M | $379.27M | (m) | $398.76M | $52.92M | -19.54% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-86.25M | $238.46M | (m) | $274.90M | $48.88M | -36.17% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |